S&P 500
5.222,68 +94,89 (+1,85%) Nasdaq
16.340,87 +184,57 (+1,14%) NIKKEI 225
38.105,89 -123,22 (-0,32%) Dólar/Euro
1,0775 +0,0002 (+0,02%) Petróleo Brent
82,52 -0,27 (-0,33%) Bitcoin EUR
56.562,31 -88,30 (-0,16%)
Vor Biopharma Inc. (VOR)
Después del cierre:
Vor Biopharma Inc.
100 Cambridgepark Drive
Suite 101
Cambridge, MA 02140
United States
617 655 6580
https://www.vorbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 168
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, CEO & Director | 943,91k | N/A | 1975 |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer | 661,98k | N/A | 1973 |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer | 660,55k | N/A | 1971 |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | N/A | N/A | 1971 |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer | 608,48k | N/A | 1977 |
| Ms. Tania Philipp | Chief People Officer | N/A | N/A | 1972 |
| Mr. John C. King M.B.A. | Chief Commercial Officer | N/A | N/A | 1976 |
| Mr. Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy & Program Management | N/A | N/A | N/A |
| Mr. David Phillips M.B.A. | Senior VP & Head of Quality | N/A | N/A | N/A |
Descripción
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Vor Biopharma Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 6; Derechos de los accionistas: 8; Compensación: 9.
